Skip to main content
Quest Diagnostics

Smart Codes

Screening for cervical cancer and STIs, simplified

Smart Codes make it easy

Delivering the care your patients need should not be complicated. Smart Codes from Quest are based on guidelines and use a patient’s age and STI risk factors to determine which combination of HPV and select STI screening, along with an image-guided Pap, should be performed.
smiling female doctor with patient

Trust Smart Codes to order appropriate guidelines-based screening for your patients

Smart Codes follow the current guidelines1-5 and help you order the appropriate screening with the right codes to deliver optimal patient care and improve practice workflow.

Cervical Cancer Screening and Average Risk for STIs (CT/NG)

Tests included with Smart Code 91384
Panel components can be ordered separately
Ages (years) 91384–Image-Guided Papa with Age-Based Screening Protocols
21-24
  • Image-Guided Pap (ThinPrep® or SurePath™)
  • High-Risk HPV mRNA (if Pap is ASC-US)
  • Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG)
25-29
  • Image-Guided Pap (ThinPrep or SurePath)
  • HPV mRNA (if Pap is ASC-US)
30-65
  • Image-Guided Pap (ThinPrep or SurePath)c
  • HPV mRNAc
  • HPV Genotyping 16, 18/45 (when Pap is normal and HPV is detected)

Cervical Cancer Screening and Average Risk for STIs (CT/NG/TRICH)

Tests included with Smart Code 91386 and 91385
Panel components can be ordered separately
Ages (years) 91386–Image-guided Papa with Age-Based Screening, with CT/NG, Trichomonas 91385–Image-guided Papa with Age-Based Screening, with CT/NG
21-24 Same as 91384, plus Trichomonas (guidelines recommend routine screening of CT/NG in women ages 21-244) Same as 91384 (guidelines recommend routine screening of CT/NG in women ages 21-244)
25-29 Same as 91384, plus CT/NG and Trichomonas Same as 91384, plus CT/NG
30-65 Same as 91384, plus CT/NG and Trichomonas Same as 91384, plus CT/NG

HPV mRNA assay (90887); Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) RNA, TMA (11363); HPV mRNA Genotypes 16, 18/45 (90942); Trichomonas vaginalis, Qualitative TMA, Pap Vial (90521)

 

Quest Diagnostics Smart Codes may not represent all of the possible screening options in published guidelines. Please contact your Quest Diagnostics representative for information on additional Pap and HPV testing options from Quest.

 

For all 3 Smart Codes, if a patient is over the age of 65: Screening should be discontinued if patient has had adequate negative prior screening resultsb and no history of CIN 2+.

 

Recommend continuing age-based screening for >=20 years in those patients with a history of CIN 2, CIN 3, or adenocarcinoma in situ. Adequate negative prior screening results is defined as 3 consecutive negative Paps or 2 consecutive negative co-tests within the past 10 years, with the most recent test occurring within the past 5 years.1-3

 

aACOG recommendations do not specify a particular type of Pap test. Both imaged and nonimaged Pap tests are acceptable under the recommendations. Information on nonimaged Pap tests can be found at QuestDiagnostics.com/TestDirectory

 

bDefined as 3 consecutive negative Paps or 2 consecutive negative co-tests within the past 10 years, with the most recent test occurring within the past 5 years.

Count on Quest for tests that deliver highly accurate results

Screening for cervical cancer has dramatically helped reduce its incidence and mortality, and co-testing with Pap and HPV together offer superior detection of risk versus either test alone.6

ThinPrep® is an image-guided Pap test using a liquid-based cytology collection system that delivers:
 

Learn more

SureSwab® (ATV) assay uses NAAT, the most reliable diagnostic test method, and yields up to:
 

Learn more

The Aptima® HPV mRNA assay detects the presence and activity of HPV infection and is shown to reduce false positives by:

Learn more

We offer support materials that make it even easier to deliver the best patient care

Download
Download

Smart Codes simplify the ordering process so you can provide the care she needs

Quest is in-network with the majority of health plans nationwide

Quanum® Solutions that help you order tests and make data-driven decisions to help streamline your practice

Over 2,250 Patient Service Centers with simple online scheduling and shorter wait times

Interface with 600+ EHR systems

Rapid test results that patients can access through MyQuest®

Use Smart Codes today to order the screening your patients need

Order screenings

​References:

  1. Women’s Preventive Services Initiative. Recommendations for well-woman care – a well-woman chart. Published August 26, 2019. Accessed August 11, 2021. https://www.womenspreventivehealth.org/wp-content/uploads/WellWomanChart.pdf
  2. ACOG. Updated cervical cancer screening guidelines. Updated April 2021. Accessed August 11, 2021. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines
  3. US Preventive Services Task Force. Cervical cancer: screening. Published August 21, 2018. Accessed August 11, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening
  4. CDC. Sexually transmitted infections treatment guidelines, 2021. Reviewed July 22, 2021. Accessed August 11, 2021. https://www.cdc.gov/std/treatment-guidelines/screening-recommendations.htm
  5. Perkins, RB, Guido, RS, Castle, PE, et al. 2019 ASCCP Risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24(RR-02): 102–131. doi:10.1097/LGT.0000000000000525
  6. Kaufman HW, Alagia DP, Chen Z, et al. Contributions of liquid-based (Papanicolaou) cytology and human papillomavirus testing in co-testing for detection of cervical cancer and precancer in the United States. Am J Clin Pathol. 2020;154(4):510-516. doi:10.1093/ajcp/aqaa074
  7. ThinPrep® 2000 system package insert. MAN-02624-001 Rev. 004. Hologic, Inc.; 2017.
  8. Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908-913. doi:10.1038/bjc.2013.22
  9. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. Int J Cancer. 2011;129(3):691-701. doi:10.1002/ijc.25726
  10. Hobbs MM, Seña AC. Modern diagnosis of Trichomonas vaginalis infection. Sex Transm Infect. 2013;89(6):434-438. doi:10.1136/sextrans-2013-051057
A clinical view on STI testing

Listen to experts discuss taking a good sexual history, screening for specific patient populations, and implementation of STI screening in your practice.

Click to learn more

Center of Excellence for fertility testing

ReproSource® empowers you to make the best decisions about patient fertility treatments, with access to a network of experts and high-quality testing.

Click to learn more

Genetic consultation available

Certified Genomic Science Specialists are available to help with test selection and results interpretation 1.866.GENE.INFO (1.866.436.3463)

Contact us

Contact us to receive additional information on our lab tests, services, and coverage

Contact us

Smart Codes

Test directory

With more than 3,500+ tests available, we can support every stage of a woman’s life with important insights

Learn more

Resources

We offer a variety of useful resources for healthcare professionals

View Resources

Patient info

For assistance with questions about the testing process or locations, call 1.866.MYQUEST (1.866.697.8378)

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.